Home › Breast Cancer › NCT06171607
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
Characterizing Breast Masses Using an Integrative Framework of Machine Learning and Radiomics
Who can join
Ages 18 and older · Women
Full eligibility criteria
Inclusion Criteria: * Newly diagnosed breast masses assigned as BIRADS 4a, 4b, 4c or 5 by conventional US and recommended for ultrasound guided biopsy * Age \>= 18 years * Female Exclusion Criteria: * Contraindications to microbubble contrast: Patients who have a known pulmonary hypertension and any known hypersensitivity to US contrast agent * Women with renal failure or insufficiency (only if patient is receiving CESM scan) * Women with Iodine contrast allergy (only if patient is receiving CESM scan) * Women with the largest side of the mass measuring ≤ 1 cm (only if patient is receiving CEUS scan) * Women who are pregnant, possibly pregnant, or lactating * Women currently undergoing neoadjuvant chemotherapy * Women \< 18 years of age * Patient ≤ 30 years (only if patient is receiving CESM scan) * Masses in the same breast that had prior lumpectomy for cancer * Women with cancer in the same breast will be excluded however, women with cancer in the contralateral breast will be eligible to participate in the study * Women with an allergy to perflutren (only if patient is receiving CEUS scan) * Prior history of biopsy for that specific lesion * Women with breast implants
About the study
This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to diagnose many diseases in the body. This trial may help researchers learn if using CEUS will help in determining whether or not an ultrasound guided biopsy is necessary.
What is being tested
- Contrast-Enhanced Ultrasound (procedure)
- Perflutren Lipid Microspheres (drug)
- Sulfur Hexafluoride Lipid Microspheres (drug)
Sponsor: University of Southern California · Participants: 100 · Started: Nov 5, 2020
Contact the study team
- Janet Jaime · Phone: 323-865-3205
Official record on ClinicalTrials.gov — NCT06171607
Locations in the U.S.
| California | Los Angeles County-USC Medical Center, Los Angeles USC / Norris Comprehensive Cancer Center, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.